Prediction of enzyme inhibition and mode of inhibitory action based on calculation of distances between hydrogen bond donor/acceptor groups of the molecule and docking analysis: An application on the discovery of novel effective PTP1B inhibitorsFootnote

^$Presented at the 8^th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, CMTPI-2015, June 21–25, 2015, Chios, Greece.

References

• M. Rask-Andersen, M. Sällman Almén, and H.B. Schiöth, Almén, and H Schiöth, Trends in the exploitation of novel drug targets, Nat. Rev. Drug Discov. 10 (2011), pp. 579–590.
   PubMed Web of Science ®Google Scholar
• P. Eleftheriou, A. Geronikaki, D. Hadjipavlou-Litina, P. Vicini, O. Filz, D. Filimonov, V. Poroikov, S. Chaudhaery, K. Roy, and A. Saxena, Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/ lipoxygenase inhibitors, Eur. J. Med. Chem. 47 (2012), pp. 111–124.
   PubMed Web of Science ®Google Scholar
• Y. Cao, T. Jiang, and T. Girke, A maximum common substructure-based algorithm for searching and predicting drug-like compounds, Bioinformatics 24 (2008), pp. 366–374.
   Web of Science ®Google Scholar
• J. Masciocchi, G. Frau1, M. Fanton, M. Sturlese, M. Floris, L. Pireddu, P. Palla, F. Cedrati, P. Rodriguez-Tome, and S. Moro, MMsINC: A large-scale chemoinformatics database, Nucleic Acids Res. 37 (2009), pp. 284–290.
   PubMed Web of Science ®Google Scholar
• A. Geronikaki, A. Lagunin, D. Hadjipavlou-Litina, P. Elefteriou, D. Filimonov, V. Poroikov, I. Alam, and A. Saxena, Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition, J. Med. Chem. 51 (2008), pp. 1601–1609.
   PubMed Web of Science ®Google Scholar
• A. Lagunin, O. Gomazkov, D. Filimonov, T. Gureeva, E. Dilakyan, E. Kugaevskaya, Y. Elisseeva, N. Solovyeva, and V. Poroikov, Computer-aided selection of potential antihypertensive compounds with dual mechanisms of action, J. Med. Chem. 46 (2003), pp. 3326–3332.
   PubMed Web of Science ®Google Scholar
• S.Y. Huang and X. Zou, Advances and challenges in protein-ligand docking, Int. J. Mol. Sci. 11 (2010), pp. 3016–3034.
   PubMed Web of Science ®Google Scholar
• M. Bello, M. Martínez-Archundia, and J. Correa-Basurto, Automated docking for novel drug discovery, Expert Opin. Drug Discov. 8 (2013), pp. 821–34.
   PubMed Web of Science ®Google Scholar
• R.M. Knegtel, I.D. Kuntz, and C.M. Oshiro, Molecular docking to ensembles of protein structures, J. Mol. Biol. 266 (1997), pp. 424–440.
   PubMed Web of Science ®Google Scholar
• F. Osterberg, G.M. Morris, M.F. Sanner, A.J. Olson, and D.S. Goodsell, Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock, Proteins 46 (2002), pp. 34–40.
   PubMed Web of Science ®Google Scholar
• P. Eleftheriou, The protein tyrosine phosphatase 1b as a drug target for the treatment of diabetes type II. Developing effective and selective PTP1B inhibitors, ChemXPress 2 (2013), pp.72–84.
   Google Scholar
• A.J. Barr, Protein tyrosine phosphatases as drug targets: Strategies and challenges of inhibitor development, Future Med. Chem. 2 (2010), pp. 1562–1576.
   Web of Science ®Google Scholar
• Y.A. Puius, Y. Zhao, M. Sullivan, D.S. Lawrence, S.C. Almo, and Z.Y. Zhang, Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design, Proc. Natl. Acad. Sci. U S A. 94 (1997), pp. 13420–13425.
   PubMed Web of Science ®Google Scholar
• C. Wiesmann, K.J. Barr, J. Kung, J. Zhu, D.A. Erlanson, W. Shen, B.J. Fahr, M. Zhong, L. Taylor, M. Randal, R.S. McDowell, and S.K. Hansen, Allosteric inhibition of protein tyrosine phosphatase 1B, Nat. Struct. Mol. Biol. 11 (2004), pp. 730–773.
   PubMed Web of Science ®Google Scholar
• A.J. Stull, Z.Q. Wang, X.H. Zhang, Y. Yu, W.D. Johnson, and W.T. Cefalu, Skeletal muscle protein tyrosine phosphatase 1B regulates insulin sensitivity in African Americans, Diabetes 61 (2012), pp. 1415–1422.
   PubMed Web of Science ®Google Scholar
• R. Fernandez-Ruiz, E. Vieira, P.M. Garcia-Roves, R. Gomis, and T.W.H. Kay, Protein tyrosine phosphatase-1B modulates pancreatic β-cell mass, PLoS One 9 (2014), p. e90344.
   PubMed Web of Science ®Google Scholar
• T. Madej, K.J. Addess, J.H. Fong, L.Y. Geer, R.C. Geer, C.J. Lanczycki, C. Liu, S. Lu, A. Marchler-Bauer, A.R. Panchenko, J. Chen, P.A. Thiessen, Y.W. Ang, D. Zhang, and S.H. Bryant, MMDB: 3D structures and macromolecular interactions, Nucleic Acids Res. (2012), pp. D461–4.
   Google Scholar
• RCSB Protein Data Bank, www.rcsb.org/.
   Google Scholar
• H. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. Bhat, H. Weissig, I. Shindyalov, and P. Bourne, The Protein Data Bank, Nucleic Acids Res. 28 (2000), pp. 235–242.
   PubMed Web of Science ®Google Scholar
• CORINA classic 3D structure generator, www.molecular-networks.com/products/corina.
   Google Scholar
• Z. Bikadi and E. Hazai, Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock, J. Chem. Inf. 1 (2009), pp. 15–21.
   Google Scholar
• A. Geronikaki, P. Eleftheriou, P. Vicini, I. Alam, A. Dixit, and A.K. Saxena, 2-thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with shp-2 inhibitory action, J. Med. Chem. 51 (2008), pp. 5221–5228.
   PubMed Web of Science ®Google Scholar
• M. Dixit, U. Saeed, A. Kumar, M.I. Siddiqi, A.K. Tamrakar, A.K. Srivastava, and A. Goel, Synthesis, molecular docking and PTP1B inhibitory activity of functionalized 4,5-dihydronaphthofurans and dibenzofurans, Med. Chem. 4 (2008), pp. 18–24.
   PubMed Web of Science ®Google Scholar
• G. Scapin, S.B. Patel, J.W. Becker, Q. Wang, C. Desponts, D. Waddleton, K. Skorey, W. Cromlish, C. Bayly, M. Therien, J.Y. Gauthier, C.S. Li, C.K. Lau, C. Ramachandran, B.P. Kennedy, and E. Asante-Appiah, The structural basis for the selectivity of benzotriazole inhibitors of PTP1B, Biochemistry 42 (2003), pp. 11451–11459.
   PubMed Web of Science ®Google Scholar
• A. Pannifer, A. Flint, N. Tonks, and D. Barford, Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray crystallography, J. Biol. Chem. 273 (1998), pp. 10454–10462.
   PubMed Web of Science ®Google Scholar
• A. Moretto, S. Kirincich, W. Xu, M. Smith, Z. Wan, D. Wilson, B. Follows, E. Binnun, D.J. Mccarthy, K. Foreman, D. Erbe, Y. Zhang, S. Tam, and J. Lee, Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1b inhibitors, Bioorg. Med. Chem. 14 (2006), pp. 2162–1277.
   PubMed Web of Science ®Google Scholar
• S. Klopfenstein, A. Evdokimov, A. Colson, N. Fairweather, J. Neuman, M. Maier, J. Gray, G. Gerwe, G. Stake, B. Howard, J. Farmer, M. Pokross, T. Downs, B. Kasibhatla, and K. Peters, 1,2,3,4-tetrahydroisoquinolinyl sulfamic acids as phosphatase ptp1b inhibitors, Bioorg. Med. Chem. Lett. 16 (2006), pp. 1574–1578.
   PubMed Web of Science ®Google Scholar
• G. Liu, B. Szczepankiewicz, Z. Pei, D. Janowich, Z. Xin, P. Hadjuk, C. Abad-Zapatero, H. Liang, C. Hutchins, S. Fesik, S. Ballaron, M. Stashko, T. Lubben, A. Mika, B. Zinker, J. Trevillyan, and M. Jirousek, Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1b, J. Med. Chem. 46 (2003), pp. 2093–2103.
   PubMed Web of Science ®Google Scholar
• Z. Jia, Q. Ye, A. Dinaut, Q. Wang, D. Waddleton, P. Payette, C. Ramachandran, B. Kennedy, G. Hum, and S. Taylor, Structure of protein tyrosine phosphatase 1b in complex with inhibitors bearing two phosphotyrosine mimetics, J. Med. Chem. 44 (2001), pp. 4584–4594.
   PubMed Web of Science ®Google Scholar
• S. Larsen, T. Barf, C. Liljebris, P. May, D. Ogg, T. O'Sullivan, B. Palazuk, H. Schostarez, F. Stevens, and J. Bleasdale, Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1b, J. Med. Chem. 45 (2002), pp. 598–622.
   PubMed Web of Science ®Google Scholar
• E. Asante-Appiah, S. Patel, C. Desponts, J. Taylor, C. Lau, C. Dufresne, M. Therien, R. Friesen, J. Becker, Y. Leblanc, B. Kennedy, and G. Scapin, Conformation-assisted inhibition of protein-tyrosine phosphatase-1b elicits inhibitor selectivity over t-cell protein-tyrosine phosphatase, J. Biol. Chem. 281 (2006), pp. 8010–8015.
   PubMed Web of Science ®Google Scholar
• Z. Wan, J. Lee, W. Xu, D. Erbe, D. Joseph-Mccarthy, B. Follows, and Y. Zhang, Monocyclic thiophenes as protein tyrosine phosphatase 1b inhibitors: Capturing interactions with asp48, Bioorg. Med. Chem. Lett. 16 (2006), pp. 4941–4945.
   PubMed Web of Science ®Google Scholar
• B. Douty, B. Wayland, P. Ala, M. Bower, J. Pruitt, L. Bostrom, M. Wei, R. Klabe, L. Gonneville, R. Wynn, T. Burn, P.C. Liu, A. Combs, and E. Yue, Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines, Bioorg. Med. Chem. Lett. 18 (2008), pp. 66–71.
   PubMed Web of Science ®Google Scholar
• J. Bleasdale, D. Ogg, B. Palazuk, C. Jacob, M. Swanson, X. Wang, D. Thompson, R. Conradi, W. Mathews, A. Laborde, C. Stuchly, A. Heijbel, K. Bergdahl, C.A. Bannow, C. Smith, C. Svensson, C. Liljebris, H. Schostarez, P. May, F. Stevens, and S. Larsen, Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1b and augment insulin action, Biochemistry 40 (2001), pp. 5642–5654.
   PubMed Web of Science ®Google Scholar
• J. Sun, A. Fedorov, S. Lee, X. Guo, K. Shen, D. Lawrence, S. Almo, and Z. Zhang, Crystal structure of ptp1b complexed with a potent and selective bidentate inhibitor, J. Biol. Chem. 278 (2003), pp. 12406–12414.
   PubMed Web of Science ®Google Scholar
• B. Douty, B. Wayland, P.J. Ala, M.J. Bower, J. Pruitt, L. Bostrom, M. Wei, R. Klabe, L. Gonneville, R. Wynn, T.C. Burn, P.C. Liu, A.P. Combs, and E.W. Yue, Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines, Bioorg. Med. Chem. Lett. 18 (2008), pp. 66–71.
   PubMed Web of Science ®Google Scholar
• R. Cer1, U. Mudunuri1, R. Stephens, and F. Lebeda, IC50-to-Ki: A web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding, Nucleic Acids Res. 37 (2009) Web Server issue W441–W445.
   Google Scholar